APDs are the mainstay of treatment in schizophrenia patients, while the Akt/GSK3/mTORC1 pathway has been implicated in APD mechanisms of action and therapeutic effects.9,12,13 Thus, we proceeded in analysis of PBMC samples of 32 patients that were available after treatment with olanzapine or risperidone for 6 weeks. Here, AKT1 is linked to schizophrenia.